Replies to post #297955 on Innovation Pharmaceuticals Inc (IPIX)

[Tonyeight]

better == BETTER BE IN IT == ANY DAY POP UP TO $== THING ARE BREWING WELL $IPIX

[LilyGDog]

Great post! Thanks Farrell90!

Go Leo & IPIX!

"Thanks, nice post. I agree with most of your comments,but oral Brilacidin has been shown numerous times to not be absorbed systemically. A number of reports have shown a GI form of Covid 19 which could respond to oral therapy. I am not aware of any reports linking the GI disorder with later severe pulmonary failure.IMO Brillacidin for Coronovirus will be limited to IV therapy at this time.

IPIX has hinted at the development of an inhaler for Brilacidin to be used for COVID 19 and a diverse group of pulmonary disorders such as asthma, Copd, cystic fibrosis. Hopefully they can receive funding for the inhaler for Covid19. Approval would open the door to the lucrative lung disease market and would be a significant therapeutic addition to treatment as inhaled steroids and bronchodilators have significant side effects.

CytoDan's Leronlimab is an interesting drug. Its antiviral MOA is to prevent viral cell attachment which may be complimentary to Brilacidin.

Influenza is a RNA virus which seems to have structural similarities to Covid 19. Brilacidin could be a possible treatment for influenza pneumonitis which would be an exciting addition.

I agree we have enough data to warrant clinical trials for Brilacidn for Covid 19. IPIX has stated they are being planned and an announcement could only be weeks away.

I expect the flow of funds into IPIX will increase week to week as the news gets out. It really does have that much potential.

I am glad I am not short.The ride from the $4.90 high could end abruptly...very soon.

GLTA Farrell"

[Luckytouch]

Always find your posts very helpful. You reference several studies that determined that B isn’t systemically absorbed. I remember the UP/UPS determined that absorption systemically was minimal which was good for us because it indicated the decreased likelihood of SE and I believe B was evaluated for the effects of stomach contents on B but I can’t find anything that has determined there is no absorption through the SI. A link would be great if you can. Thanks.

[KMBJN]

Agree that inhaled brilacidin would be very interesting. Heck any trial they can run with brilacidin would be interesting. We need to get going with some more trials, if we have the funds or can secure grant money or partners to fund.

Leronlimab blocks HIV entering immune cells by blocking chemokine receptor CCR5 on CD4 T-cells. It has no direct antiviral activity against SARS2, although it does help restore the immune system so it can do its job to remove SARS2 (by keeping TRegs away, and also somehow by restoring lowered CD4 and CD8 T-cell counts). It is an immunomodulator primarily (blocking CCR5 receptor on immune cells). It is extremely promising in many indications (HIV, cancer, COVID-19, autoimmune disease, inflammatory diseases in general), and I have made it my largest biotech holding.

With more lab results expected to come out for brilacidin soon, it may be time to top-up IPIX for a bump with results.

[GreenBioAnalyst]

You wrote:
Thanks, nice post. I agree with most of your comments, but oral Brilacidin has been shown numerous times to not be absorbed systemically.

First of all, the IV portion of Bril is systematically absorbed with 100% bioavailability in plasma protein of the blood! However, you are right about the IBD/UC po drug intentionally made by Oralogic to treat IBD/UC and to have very limited systemic absorption, as such it was intended to go target the colon. But at this point, the po version for IBD/UC will not be repurposed, so that leaves us with the IV option only for the interim period. The possibility is there to come up with po form for prophylaxis to prevent and even address mild cv19 occurrence. But that's another story just as your inhaler idea as well. However, repurposing the po version may give us another opportunity in the GI portion since some patients are experiencing abnormalities with thickening of the bowel wall and ischemia. SARsCoV2 viral replication as the culprit in the intestine as the explanatory cause.

I'm not sure why you brought this up?
"I am not aware of any reports linking the GI disorder with later severe pulmonary failure."

SARsCOV2 maybe RNA based compared to influenza but they do not share the same homology from each other in terms of structure. SARsCOv is 83% and MERsCoV is 56% and a big drop off from the rest of other flu pandemics such as H1N1, etc., etc. But my point was, if the Juggernaut (character) Bril can address CV19, then it's more likely to be the key or the backbone of future therapeutic for pandemic flu to shorten the duration or episode that leads to their pathogenesis.

Do you think the LEO doesn't read this site? Obviously, I did mention Remdesivir as a potential placebo to send shock waves, but it's a coincidence that the drug was mentioned too. That drug has serious renal and liver concerns with cv19 patients and a much higher death rate than what was originally disclosed that came out of China.

We have a great drug here and I'm very confident for damn good success in the human lungs and other results we are waiting. Binding should be much faster with h l epithelial cells. Sp should easily fill the 1.84 gap. But no doubt with any funding we will hit $3. Let's hope we get multiple grants and big funding from the government so we can get to $4+ after the trial is initiated. GLTA! Black Diamond in here.

TAGB